Balyasny Asset Management’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.81M | Sell |
7,980
-5,688
| -42% | -$2.03M | ﹤0.01% | 1628 |
|
|
2025
Q4 | $4.47M | Buy |
13,668
+2,286
| +20% | +$725K | 0.01% | 1455 |
|
|
2025
Q3 | $3.21M | Buy |
11,382
+7,418
| +187% | +$2.15M | ﹤0.01% | 1586 |
|
|
2025
Q2 | $1.11M | Buy |
+3,964
| New | +$1.12M | ﹤0.01% | 2006 |
|
|
2025
Q1 | – | Sell |
-8,072
| Closed | -$2.38M | – | 2760 |
|
|
2024
Q4 | $2.1M | Sell |
8,072
-290,176
| -97% | -$86.1M | ﹤0.01% | 1658 |
|
|
2024
Q3 | $96.1M | Buy |
298,248
+290,467
| +3,733% | +$95M | 0.16% | 138 |
|
|
2024
Q2 | $2.43M | Buy |
7,781
+3,591
| +86% | +$1.05M | ﹤0.01% | 1459 |
|
|
2024
Q1 | $1.19M | Sell |
4,190
-1,645
| -28% | -$481K | ﹤0.01% | 1712 |
|
|
2023
Q4 | $1.68M | Sell |
5,835
-133,880
| -96% | -$36.5M | ﹤0.01% | 1507 |
|
|
2023
Q3 | $37.5M | Sell |
139,715
-119,537
| -46% | -$29.8M | 0.08% | 356 |
|
|
2023
Q2 | $57.6M | Buy |
+259,252
| New | +$60.2M | 0.13% | 221 |
|
|
2022
Q2 | – | Sell |
-9,081
| Closed | -$2.23M | – | 2718 |
|
|
2022
Q1 | $2.2M | Buy |
+9,081
| New | +$2.09M | 0.01% | 1311 |
|
|
2021
Q4 | – | Sell |
-196,986
| Closed | -$41.9M | – | 2200 |
|
|
2021
Q3 | $41.9M | Buy |
196,986
+178,126
| +944% | +$41M | 0.17% | 143 |
|
|
2021
Q2 | $4.6M | Sell |
18,860
-24,391
| -56% | -$6M | 0.02% | 741 |
|
|
2021
Q1 | $10.8M | Sell |
43,251
-145,472
| -77% | -$34.7M | 0.05% | 465 |
|
|
2020
Q4 | $43.4M | Buy |
+188,723
| New | +$43.5M | 0.24% | 95 |
|
|
2020
Q1 | – | Sell |
-17,299
| Closed | -$4.17M | – | 1130 |
|
|
2019
Q4 | $4.17M | Sell |
17,299
-77,448
| -82% | -$17.1M | 0.02% | 627 |
|
|
2019
Q3 | $18.3M | Buy |
94,747
+67,388
| +246% | +$12.9M | 0.13% | 253 |
|
|
2019
Q2 | $5.04M | Buy |
27,359
+15,572
| +132% | +$2.79M | 0.03% | 604 |
|
|
2019
Q1 | $2.24M | Buy |
11,787
+3,644
| +45% | +$696K | 0.01% | 788 |
|
|
2018
Q4 | $1.58M | Sell |
8,143
-12,890
| -61% | -$2.51M | 0.01% | 769 |
|
|
2018
Q3 | $4.36M | Buy |
21,033
+3,608
| +21% | +$711K | 0.02% | 750 |
|
|
2018
Q2 | $3.22M | Buy |
+17,425
| New | +$3.08M | 0.01% | 789 |
|
|
2018
Q1 | – | Sell |
-10,245
| Closed | -$1.78M | – | 1905 |
|
|
2017
Q4 | $1.78M | Sell |
10,245
-50,252
| -83% | -$8.89M | 0.01% | 1167 |
|
|
2017
Q3 | $11.3M | Buy |
+60,497
| New | +$10.7M | 0.04% | 466 |
|
|
2017
Q2 | – | Sell |
-7,500
| Closed | -$1.22M | – | 1448 |
|
|
2017
Q1 | $1.23M | Sell |
7,500
-3,527
| -32% | -$586K | 0.01% | 1042 |
|
|
2016
Q4 | $1.61M | Sell |
11,027
-371,420
| -97% | -$55.9M | 0.01% | 920 |
|
|
2016
Q3 | $63.8M | Buy |
382,447
+107,439
| +39% | +$18.2M | 0.37% | 68 |
|
|
2016
Q2 | $41.8M | Buy |
275,008
+215,074
| +359% | +$33.4M | 0.27% | 96 |
|
|
2016
Q1 | $8.99M | Sell |
59,934
-220,573
| -79% | -$32.8M | 0.05% | 424 |
|
|
2015
Q4 | $45.5M | Buy |
280,507
+126,557
| +82% | +$19.9M | 0.32% | 89 |
|
|
2015
Q3 | $21.3M | Buy |
153,950
+16,983
| +12% | +$2.68M | 0.16% | 174 |
|
|
2015
Q2 | $21M | Buy |
+136,967
| New | +$21.9M | 0.13% | 206 |
|
|
2015
Q1 | – | Sell |
-142,772
| Closed | -$22.7M | – | 930 |
|
|
2014
Q4 | $22.7M | Sell |
142,772
-184,501
| -56% | -$28.7M | 0.21% | 139 |
|
|
2014
Q3 | $46M | Buy |
+327,273
| New | +$42.7M | 0.36% | 57 |
|
Other funds holding AMGN
VCM
VPM
Balyasny Asset Management's AMGN Position: Q1 2026 in Review
Balyasny Asset Management reduced its Amgen (AMGN) stake by 42% in Q1 2026, selling an estimated $2.03M and leaving 7,980 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.
Balyasny Asset Management first reported a position in AMGN in Q3 2014 and has held it in 35 quarters since. The position peaked at $96.1M in Q3 2024. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Balyasny Asset Management held 7,980 shares of Amgen worth $2.81M as of Q1 2026.
- Balyasny Asset Management sold 5,688 Amgen shares in Q1 2026, an estimated $2.03M.
- Amgen made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1628 holding.
- Balyasny Asset Management first reported a position in Amgen in Q3 2014 and has held it in 35 quarters since.
- Balyasny Asset Management's Amgen position peaked at $96.1M in Q3 2024.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.